AbbVie faces US antitrust claims over Humira

( January 17, 2025, 23:31 GMT | Official Statement) -- MLex Summary: A proposed US class action accuses AbbVie of conspiring to block biosimilar competition to its brand name drug Humira. According to the complaint, AbbVie entered into agreements with pharmacy benefit managers whereby, in exchange for payments, the PBMs ensured Humira would be positioned favorably on formularies, thereby thwarting the biosimilar competitors’ ability to win sales.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Prepare for tomorrow’s regulatory change, today

Documents

Related Sections